Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06437171 · ClinicalTrials.gov registry record · Phase 4
FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA
A Phase 4 study of Food Allergy, sponsored by AAADRS Clinical Research Center.
- Active
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06437171 is a Phase 4 study of Food Allergy that is active but no longer recruiting, run by AAADRS Clinical Research Center. The registered enrollment target is 20 participants, below the 963-participant average among 17 other Food Allergy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06437171, a Phase 4 study of Food Allergy, is active but no longer recruiting, sponsored by AAADRS Clinical Research Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
Conditions Studied
Interventions
- BIOLOGICAL Omalizumab
Study Locations (1)
Florida
- AAADRS Clinical Research Center - Coral Gables
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-06-03 |
| Est. Completion | 2026-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06437171
The ClinicalTrials.gov registry entry for NCT06437171 describes a study currently listed as active not recruiting, categorized as Phase 4. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 963-participant average among 17 other Food Allergy trials with a reported enrollment target (98% lower). The listed sponsor is AAADRS Clinical Research Center, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Food Allergy appearing as the primary indexed condition, and to 1 intervention - of which Omalizumab is the first listed.
NCT06437171 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06437171 about?
NCT06437171 is a clinical study titled "FeNO as a Marker of Allergic Reactions to OFC and Response of OMA Treatment in Multiple FA". This is a Phase IV, open-label, single-center study to evaluate the change in FeNO as a marker of clinical response to OMA in participants with multiple FA.
What is the current status of trial NCT06437171?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2024-06-03. Estimated completion is 2026-12.
What conditions does trial NCT06437171 study?
This clinical trial studies the following conditions: Food Allergy.
What interventions are being tested in trial NCT06437171?
The interventions under investigation include: Omalizumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT06437171?
This trial is sponsored by AAADRS Clinical Research Center, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06437171 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Food Allergy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Omalizumab in the Skin of Food Allergy Patients
RECRUITING · Phase 4
-
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
RECRUITING
-
Short-Term Linvoseltamab Treatment on Top of Chronic Dupilumab Treatment for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy
RECRUITING · Phase 1
-
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
RECRUITING · Phase 2
-
Natural History and Genetics of Food Allergy and Related Conditions
RECRUITING
-
Michigan Food and Atopic Dermatitis (M-FAD) Program - Molecular Analytics Project
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.